Mankind Pharma (NSE: MANKIND, BSE: 543904) is a New Delhi, Delhi-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹1,09,870 Cr, it ranks #108 by market cap among the 6,197 Indian listed companies on FinBizNet, and #6 of 86 in Medicinal Chemicals and Botanical Products. At ₹2,640.00 (as of 16 Nov 2026), the share price is 2.4% below its 52-week high of ₹2,705.00 and 38.2% above its 52-week low of ₹1,909.70. The share price is up 16.7% over one year and up 9.8% over three months.
| Current Price | ₹2,640.00 |
|---|---|
| Market Cap | ₹1,09,870 Cr |
| NSE Symbol | MANKIND |
| BSE Code | 543904 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 57 |
| Return on Equity | 12.45% |
| Return on Assets | 6.31% |
| 52-Week Range | ₹1,909.70 – ₹2,705.00 |
| 1-Year Price Change | +16.7% |
| 3-Month Price Change | +9.8% |
| Beta (1Y) | 0.37 |
| Dividend Yield | 0.08% |
| Headquarters | New Delhi, Delhi |
| Website | www.mankindpharma.com |
| Revenue | ₹4,338 Cr |
|---|---|
| Net Profit | ₹716 Cr |
| Net Margin | 16.5% |
| EPS (Basic) | ₹17.23 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Mankind Pharma reported revenue of ₹4,338 Cr in Q2 FY27, up 17.3% from ₹3,697 Cr in Q2 FY26 and up 7.6% from ₹4,031 Cr in Q1 FY27. It posted a net profit of ₹716 Cr for the quarter, against a net profit of ₹520 Cr in Q2 FY26 (up 37.7%). Across the 6 quarters from Q1 FY26 to Q2 FY27, quarterly revenue ranged from ₹3,443 Cr (Q4 FY26) to ₹4,338 Cr (Q2 FY27). The company was profitable in each of these 6 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹4,338 Cr | ₹716 Cr | 16.5% |
| Q1 FY27 | ₹4,031 Cr | ₹574 Cr | 14.2% |
| Q4 FY26 | ₹3,443 Cr | ₹559 Cr | 16.2% |
| Q3 FY26 | ₹3,567 Cr | ₹414 Cr | 11.6% |
| Q2 FY26 | ₹3,697 Cr | ₹520 Cr | 14.1% |
| Q1 FY26 | ₹3,570 Cr | ₹445 Cr | 12.5% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 72.62% of Mankind Pharma's shares as of Sept 2026, against 72.67% in Sept 2025 (−0.05 percentage points). Delivery averaged 50.3% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory diseases, etc. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, oral contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. In addition, the company engages in the trading and exporting of pharmaceutical and health care products; manufacture of packing materials, ayurvedic products, and consumer goods; real estate, leasing, and hospitality businesses; trading of agricultural products; and provision of IT services. It offers its products under the Manforce, Moxi Kind-Cv, AmLokind-At, Unwanted-Kit, Prega News, Dydroboo
1. Pharmaceuticals-This segment develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products. 2. 0-0 3. 0-0 4. 0-0
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Glenmark Pharmaceuticals Limited | ₹75,556 Cr | 55.1 | 14.07% | ₹4,157 Cr | +45.7% |
Listed by market capitalisation. Ratios are shown for context only.
Mankind Pharma is trading at ₹2,640.00, with a market capitalisation of ₹1,09,870 Cr.
Mankind Pharma operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Mankind Pharma has a P/E of 57 and a return on equity of 12.45%.
Mankind Pharma is listed on the NSE under the symbol MANKIND and on the BSE under the scrip code 543904.
Mankind Pharma's share price is up 16.7% over one year and up 9.8% over three months. Its 52-week range is ₹1,909.70 to ₹2,705.00.
In Q2 FY27, Mankind Pharma reported revenue of ₹4,338 Cr and net profit of ₹716 Cr, with basic EPS of ₹17.23 (consolidated, parsed from the company's exchange filing).
Mankind Pharma reported revenue of ₹4,338 Cr in Q2 FY27, up 17.3% from ₹3,697 Cr in Q2 FY26 and up 7.6% from ₹4,031 Cr in Q1 FY27.
Promoters held 72.62% of Mankind Pharma's shares as of Sept 2026, against 72.67% in Sept 2025 (−0.05 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.